Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Jan 23;93(2):754–758. doi: 10.1073/pnas.93.2.754

Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint.

C M Flory 1, P A Pavco 1, T C Jarvis 1, M E Lesch 1, F E Wincott 1, L Beigelman 1, S W Hunt 3rd 1, D J Schrier 1
PMCID: PMC40127  PMID: 8570629

Abstract

Catalytic RNA molecules, or ribozymes, have generated significant interest as potential therapeutic agents for controlling gene expression. Although ribozymes have been shown to work in vitro and in cellular assays, there are no reports that demonstrate the efficacy of synthetic, stabilized ribozymes delivered in vivo. We are currently utilizing the rabbit model of interleukin 1-induced arthritis to assess the localization, stability, and efficacy of exogenous antistromelysin hammerhead ribozymes. The matrix metalloproteinase stromelysin is believed to be a key mediator in arthritic diseases. It seems likely therefore that inhibiting stromelysin would be a valid therapeutic approach for arthritis. We found that following intraarticular administration ribozymes were taken up by cells in the synovial lining, were stable in the synovium, and reduced synovial interleukin 1 alpha-induced stromelysin mRNA. This effect was demonstrated with ribozymes containing various chemical modifications that impart nuclease resistance and that recognize several distinct sites on the message. Catalytically inactive ribozymes were ineffective, thus suggesting a cleavage-mediated mechanism of action. These results suggest that ribozymes may be useful in the treatment of arthritic diseases characterized by dysregulation of metalloproteinase expression.

Full text

PDF
754

Images in this article

756Fig. 1
on p.756
756Fig. 2
on p.756
756Fig. 3
on p.756

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beigelman L., McSwiggen J. A., Draper K. G., Gonzalez C., Jensen K., Karpeisky A. M., Modak A. S., Matulic-Adamic J., DiRenzo A. B., Haeberli P. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem. 1995 Oct 27;270(43):25702–25708. doi: 10.1074/jbc.270.43.25702. [DOI] [PubMed] [Google Scholar]
  2. Bennett C. F., Condon T. P., Grimm S., Chan H., Chiang M. Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 1994 Apr 1;152(7):3530–3540. [PubMed] [Google Scholar]
  3. Bonassar L. J., Frank E. H., Murray J. C., Paguio C. G., Moore V. L., Lark M. W., Sandy J. D., Wu J. J., Eyre D. R., Grodzinsky A. J. Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum. 1995 Feb;38(2):173–183. doi: 10.1002/art.1780380205. [DOI] [PubMed] [Google Scholar]
  4. Brinckerhoff C. E., Auble D. T. Regulation of collagenase gene expression in synovial fibroblasts. Ann N Y Acad Sci. 1990;580:355–374. doi: 10.1111/j.1749-6632.1990.tb17944.x. [DOI] [PubMed] [Google Scholar]
  5. Castanotto D., Rossi J. J., Deshler J. O. Biological and functional aspects of catalytic RNAs. Crit Rev Eukaryot Gene Expr. 1992;2(4):331–357. [PubMed] [Google Scholar]
  6. Christoffersen R. E., Marr J. J. Ribozymes as human therapeutic agents. J Med Chem. 1995 Jun 9;38(12):2023–2037. doi: 10.1021/jm00012a001. [DOI] [PubMed] [Google Scholar]
  7. Crow J. F. The high genomic mutation rate. Curr Biol. 1992 Nov;2(11):605–607. doi: 10.1016/0960-9822(92)90171-6. [DOI] [PubMed] [Google Scholar]
  8. Efrat S., Leiser M., Wu Y. J., Fusco-DeMane D., Emran O. A., Surana M., Jetton T. L., Magnuson M. A., Weir G., Fleischer N. Ribozyme-mediated attenuation of pancreatic beta-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2051–2055. doi: 10.1073/pnas.91.6.2051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flory C. M., Jones M. L., Warren J. S. Pulmonary granuloma formation in the rat is partially dependent on monocyte chemoattractant protein 1. Lab Invest. 1993 Oct;69(4):396–404. [PubMed] [Google Scholar]
  10. Funato T., Shitara T., Tone T., Jiao L., Kashani-Sabet M., Scanlon K. J. Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem Pharmacol. 1994 Oct 7;48(7):1471–1475. doi: 10.1016/0006-2952(94)90572-x. [DOI] [PubMed] [Google Scholar]
  11. Guerrier-Takada C., Gardiner K., Marsh T., Pace N., Altman S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell. 1983 Dec;35(3 Pt 2):849–857. doi: 10.1016/0092-8674(83)90117-4. [DOI] [PubMed] [Google Scholar]
  12. Heidenreich O., Benseler F., Fahrenholz A., Eckstein F. High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates. J Biol Chem. 1994 Jan 21;269(3):2131–2138. [PubMed] [Google Scholar]
  13. Hembry R. M., Bagga M. R., Reynolds J. J., Hamblen D. L. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis. 1995 Jan;54(1):25–32. doi: 10.1136/ard.54.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Henney A. M., Wakeley P. R., Davies M. J., Foster K., Hembry R., Murphy G., Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8154–8158. doi: 10.1073/pnas.88.18.8154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hutchinson N. I., Lark M. W., MacNaul K. L., Harper C., Hoerrner L. A., McDonnell J., Donatelli S., Moore V., Bayne E. K. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin-1 beta. Arthritis Rheum. 1992 Oct;35(10):1227–1233. doi: 10.1002/art.1780351016. [DOI] [PubMed] [Google Scholar]
  16. Izant J. G., Weintraub H. Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell. 1984 Apr;36(4):1007–1015. doi: 10.1016/0092-8674(84)90050-3. [DOI] [PubMed] [Google Scholar]
  17. Kiehntopf M., Brach M. A., Licht T., Petschauer S., Karawajew L., Kirschning C., Herrmann F. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 1994 Oct 3;13(19):4645–4652. doi: 10.1002/j.1460-2075.1994.tb06787.x. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  18. Kobayashi H., Dorai T., Holland J. F., Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994 Mar 1;54(5):1271–1275. [PubMed] [Google Scholar]
  19. Kruger K., Grabowski P. J., Zaug A. J., Sands J., Gottschling D. E., Cech T. R. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell. 1982 Nov;31(1):147–157. doi: 10.1016/0092-8674(82)90414-7. [DOI] [PubMed] [Google Scholar]
  20. Larsson S., Hotchkiss G., Andäng M., Nyholm T., Inzunza J., Jansson I., Ahrlund-Richter L. Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucleic Acids Res. 1994 Jun 25;22(12):2242–2248. doi: 10.1093/nar/22.12.2242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mehraban F., Kuo S. Y., Riera H., Chang C., Moskowitz R. W. Prostromelysin and procollagenase genes are differentially up-regulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. Arthritis Rheum. 1994 Aug;37(8):1189–1197. doi: 10.1002/art.1780370813. [DOI] [PubMed] [Google Scholar]
  22. Miyazaki K., Umenishi F., Funahashi K., Koshikawa N., Yasumitsu H., Umeda M. Activation of TIMP-2/progelatinase A complex by stromelysin. Biochem Biophys Res Commun. 1992 Jun 30;185(3):852–859. doi: 10.1016/0006-291x(92)91705-u. [DOI] [PubMed] [Google Scholar]
  23. Murphy G., Hembry R. M. Proteinases in rheumatoid arthritis. J Rheumatol Suppl. 1992 Jan;32:61–64. [PubMed] [Google Scholar]
  24. Ogata Y., Enghild J. J., Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992 Feb 25;267(6):3581–3584. [PubMed] [Google Scholar]
  25. Okada Y., Shinmei M., Tanaka O., Naka K., Kimura A., Nakanishi I., Bayliss M. T., Iwata K., Nagase H. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest. 1992 Jun;66(6):680–690. [PubMed] [Google Scholar]
  26. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sioud M., Natvig J. B., Førre O. Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol. 1992 Feb 20;223(4):831–835. doi: 10.1016/0022-2836(92)90244-e. [DOI] [PubMed] [Google Scholar]
  28. Snyder D. S., Wu Y., Wang J. L., Rossi J. J., Swiderski P., Kaplan B. E., Forman S. J. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood. 1993 Jul 15;82(2):600–605. [PubMed] [Google Scholar]
  29. Stetler-Stevenson W. G., Aznavoorian S., Liotta L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–573. doi: 10.1146/annurev.cb.09.110193.002545. [DOI] [PubMed] [Google Scholar]
  30. Suzuki K., Enghild J. J., Morodomi T., Salvesen G., Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry. 1990 Nov 6;29(44):10261–10270. doi: 10.1021/bi00496a016. [DOI] [PubMed] [Google Scholar]
  31. Uhlenbeck O. C. A small catalytic oligoribonucleotide. Nature. 1987 Aug 13;328(6131):596–600. doi: 10.1038/328596a0. [DOI] [PubMed] [Google Scholar]
  32. Ventura M., Wang P., Franck N., Saragosti S. Ribozyme targeting of HIV-1 LTR. Biochem Biophys Res Commun. 1994 Sep 15;203(2):889–898. doi: 10.1006/bbrc.1994.2266. [DOI] [PubMed] [Google Scholar]
  33. Villa A. E., Guzman L. A., Poptic E. J., Labhasetwar V., D'Souza S., Farrell C. L., Plow E. F., Levy R. J., DiCorleto P. E., Topol E. J. Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res. 1995 Apr;76(4):505–513. doi: 10.1161/01.res.76.4.505. [DOI] [PubMed] [Google Scholar]
  34. Wagner R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994 Nov 24;372(6504):333–335. doi: 10.1038/372333a0. [DOI] [PubMed] [Google Scholar]
  35. Werb Z., Alexander C. M., Adler R. R. Expression and function of matrix metalloproteinases in development. Matrix Suppl. 1992;1:337–343. [PubMed] [Google Scholar]
  36. Wincott F., DiRenzo A., Shaffer C., Grimm S., Tracz D., Workman C., Sweedler D., Gonzalez C., Scaringe S., Usman N. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 1995 Jul 25;23(14):2677–2684. doi: 10.1093/nar/23.14.2677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Woessner J. F., Jr Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991 May;5(8):2145–2154. [PubMed] [Google Scholar]
  38. Yang J. H., Usman N., Chartrand P., Cedergren R. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry. 1992 Jun 2;31(21):5005–5009. doi: 10.1021/bi00136a013. [DOI] [PubMed] [Google Scholar]
  39. Yu M., Poeschla E., Yamada O., Degrandis P., Leavitt M. C., Heusch M., Yees J. K., Wong-Staal F., Hampel A. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology. 1995 Jan 10;206(1):381–386. doi: 10.1016/s0042-6822(95)80053-0. [DOI] [PubMed] [Google Scholar]
  40. Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978 Jan;75(1):280–284. doi: 10.1073/pnas.75.1.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zaug A. J., Been M. D., Cech T. R. The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature. 1986 Dec 4;324(6096):429–433. doi: 10.1038/324429a0. [DOI] [PubMed] [Google Scholar]
  42. Zaug A. J., Grabowski P. J., Cech T. R. Autocatalytic cyclization of an excised intervening sequence RNA is a cleavage-ligation reaction. Nature. 1983 Feb 17;301(5901):578–583. doi: 10.1038/301578a0. [DOI] [PubMed] [Google Scholar]
  43. Zhao J. J., Pick L. Generating loss-of-function phenotypes of the fushi tarazu gene with a targeted ribozyme in Drosophila. Nature. 1993 Sep 30;365(6445):448–451. doi: 10.1038/365448a0. [DOI] [PubMed] [Google Scholar]
  44. Zhou C., Bahner I. C., Larson G. P., Zaia J. A., Rossi J. J., Kohn E. B. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 1994 Nov 4;149(1):33–39. doi: 10.1016/0378-1119(94)90409-x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES